PRIMARY STUDY
Renoprotective effect of telmisartan in patients with chronic kidney disease
Key Findings: In hypertensive patients with chronic kidney disease (CKD) urinary liver-type fatty acid binding protein (L-FABP) excretion and urinary collagen IV decreased significantly after treatment with the angiotensin receptor blocker telmisartan.
Type of Study: Clinical Trial
Study Sample Size: 30
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2008
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Nakamura T, et al. Renoprotective effect of telmisartan in patients with chronic kidney disease. Clin Exp Hypertens. 2008; 30:662-72. doi: 10.1080/10641960802443373
Authors: Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Node K
